2026 ASCP Annual Meeting
410 abstracts
-
NOVEL TARGETS AND TREATMENTS FOR STIMULANT USE DISORDERS AND DEPRESSION
-
SOCIAL-NEUROBEHAVIORAL PHENOTYPES FOR ADVANCEMENT OF SOCIAL-TARGET INTERVENTION IN COCAINE USE DISORDER
-
FEASIBILITY AND PRELIMINARY EFFICACY OF TIRZEPATIDE FOR INDIVIDUALS WITH MODERATE/SEVERE METHAMPHETAMINE USE DISORDER
-
ACCELERATED COURSE OF INTERMITTENT THETA BURST FOR METHAMPHETAMINE USE DISORDER: FEASIBILITY AND EEG-DERIVED FUNCTIONAL CONNECTIVITY CORRELATES OF TREATMENT RESPONSE
-
INTEGRATING COGNITIVE-BEHAVIORAL THERAPY WITH REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (CBT/TMS): A NOVEL COMBINED NEUROMODULATION-PSYCHOTHERAPY MODEL FOR PRENATAL DEPRESSION
-
CONDUCTING CLINICAL TRIALS USING COMBINED TREATMENT MODALITIES: CHALLENGES, OPPORTUNITIES, AND INSIGHTS FOR FUTURE REGULATORY CONSIDERATION
-
COGNITIVE BEHAVIORAL THERAPY FOLLOWING ESKETAMINE FOR MAJOR DEPRESSION AND SUICIDAL IDEATION FOR RELAPSE PREVENTION: THE CBT-ENDURE STUDY
-
INTERIM DATA FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ACCELERATED TRANSCRANIAL MAGNETIC INTERMITTENT THETA-BURST STIMULATION AND ADJUNCTIVE D-CYCLOSERINE FOR SUICIDAL IDEATION
-
SYNERGISTIC BIOBEHAVIORAL TREATMENTS TO REDUCE DEPRESSION AND COMPULSIVITY
-
NOVEL THERAPEUTICS WITH ENTACTOGENIC EFFECTS - A NEW FRONTIER FOR MOOD AND ANXIETY DISORDERS?
-
EMP-01 (R-MDMA) AS A NEXT-GENERATION ENTACTOGEN: MECHANISTIC RATIONALE AND THERAPEUTIC POTENTIAL IN SOCIAL ANXIETY DISORDER
-
INTRAVENOUS KETAMINE IMPROVES SOCIAL ANHEDONIA IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION AND SUICIDAL IDEATION
-
KETAMINE’S POTENTIAL FOR TREATING LONELINESS IN TREATMENT RESISTANT BIPOLAR DEPRESSION
-
OBJECTIVE MEASURES OF EMPATHY: PROSOCIAL LEARNING AND MOOD STATES
-
TARGETED INTERVENTIONS FOR SUICIDE PREVENTION
-
USING INTENSIVE, REAL-TIME MONITORING DESIGNS TO IDENTIFY PROXIMAL RISK FACTORS FOR SUICIDAL IDEATION AMONG ADOLESCENTS
-
CHANGES IN SYMPTOMS OF SUICIDAL IDEATION AND RELATED SYMPTOMS WITH TIRZEPATIDE IN INDIVIDUALS WITH MODERATE-TO-SEVERE METHAMPHETAMINE USE DISORDER
-
PSYCHOSOCIAL INTERVENTIONS FOR OLDER ADULTS WITH DEPRESSION AND VARYING DEGREES OF COGNITIVE FUNCTIONING AFTER A SUICIDE-RELATED HOSPITALIZATION
-
EFFICACY AND SAFETY OF A SINGLE DOSE OF PSILOCYBIN FOR CHRONIC ACTIVE SUICIDAL IDEATION: EXPERIENCES IN AN OPEN LABEL TRIAL
-
IMPROVING METABOLIC HEALTH IN MENTAL ILLNESS: A TRANSDIAGNOSTIC APPROACH
-
PSYMETRIC 2.0: DEVELOPMENT, REFINEMENT AND EXTERNAL VALIDATION OF CLINIC-READY CARDIOMETABOLIC PREDICTION MODELS FOR YOUNG PEOPLE WITH PSYCHOSIS SPECTRUM DISORDERS
-
TREATING PSYCHOTROPIC ASSOCIATED WEIGHT GAIN IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITY: A RETROSPECTIVE CHART REVIEW STUDY
-
PTSD AND DIABETES: A TWO-WAY STREET IN METABOLIC AND MENTAL HEALTH
-
PMCID: PMC7170451.
-
STRATEGIES TO IMPROVE TREATMENT EFFECT DETECTION IN MDD TRIALS
-
STRATEGIES TO IMPROVE TREATMENT EFFECT DETECTION IN MDD TRIALS
-
FUNCTIONAL CONNECTIVITY OF THE STRIATUM AS A BIOMARKER OF TREATMENT RESPONSE TO KCNQ-TARGETED AGENTS IN DEPRESSION
-
DEPRESSION AND DISTURBANCES IN CIRCADIAN RHYTHMS: PATHWAYS FOR NOVEL TREATMENT DEVELOPMENT
-
TOWARDS AN INTERNATIONAL, STANDARDIZED MODEL PSYCHOPHARMACOLOGY CURRICULUM FOR PSYCHIATRY RESIDENCY TRAINING: A COMPETENCY-BASED FRAMEWORK FOR IMPLEMENTATION
-
THE ASCP MODEL PSYCHOPHARMACOLOGY CURRICULUM UPDATE
-
TOWARDS AN INTERNATIONAL, STANDARDIZED MODEL PSYCHOPHARMACOLOGY CURRICULUM FOR PSYCHIATRY RESIDENCY TRAINING: A COMPETENCY-BASED FRAMEWORK FOR IMPLEMENTATION
-
TOWARDS AN INTERNATIONAL, STANDARDIZED MODEL PSYCHOPHARMACOLOGY CURRICULUM FOR PSYCHIATRY RESIDENCY TRAINING: A COMPETENCY-BASED FRAMEWORK FOR IMPLEMENTATION
-
RE104. A NOVEL SEROTONERGIC PSYCHEDELIC 4-OH-DIPT PRODRUG FOR THE TREATMENT OF POSTPARTUM DEPRESSION
-
A NEW DAWN FOR SOCIAL ANXIETY TREATMENT: CLINICAL ADVANCEMENT OF THE NOVEL V1AR ANTAGONIST, NTX-1472
-
DT-101 – A NOVEL ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE RECEPTOR (AMPAR) POSITIVE ALLOSTERIC MODULATOR DEMONSTRATES FAVORABLE TOLERABILITY AND FUNCTIONAL BIOMARKERS IN PHASE 1 HEALTHY VOLUNTEER TRIAL
-
SELTOREXANT, ADJUNCTIVE TO ANTIDEPRESSANTS, IN ADULTS WITH MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS: PHASE 3 STUDIES
-
KETAMINE TREATMENT FOR NON-MOTOR SYMPTOMS OF PARKINSON'S DISEASE
-
FORVISIRVAT (SP-624), A FIRST-IN-HUMAN SIRT6 ACTIVATOR WITH AN EPIGENETIC MECHANISM OF ACTION, CURRENTLY IN A PHASE 2B-3 STUDY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
-
UNLOCKING MEDICINES FOR NEUROPSYCHIATRY BY ENHANCING ORAL ABSORPTION USING A LYMPHATIC-TARGETING PRODRUG TECHNOLOGY
-
BH-200 (NELIVAPTAN), A VASOPRESSIN V1B RECEPTOR ANTAGONIST, IN GENETICALLY DEFINED SUBGROUPS OF MDD: PRECISION TARGETING OF HPA-AXIS DYSREGULATION IN THE OLIVE PHASE 2 PROGRAM
-
NOVEL ORAL RAPID-ACTING NEUROACTIVE STEROID FOR TREATMENT OF POSTPARTUM DEPRESSION: A PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL OF LPCN 1154A
-
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE FATTY ACID AMIDE HYDROLASE INHIBITOR PALMITOYLETHANOLAMIDE IN BIPOLAR DEPRESSION
-
PROSPECTIVE REPLICATION OF AN EEG BIOMARKER FOR PREDICTING CHANGES IN ATTENTION IN ALTO-203, AN H3 INVERSE AGONIST
-
FINDINGS FROM THE ASCP PRESIDENTIAL TASK FORCE ON PSYCHOTROPIC DRUG POLYPHARMACOTHERAPY
-
UNDERUTILIZED AUGMENTERS IN POLYPHARMACY REGIMENS: THE CASE FOR LITHIUM
-
RATIONAL AND IRRATIONAL PSYCHOPHARMACOLOGY COMBINATIONS
-
WHEN TO SWITCH VERSUS AUGMENT PHARMACOTHERAPIES
-
MONDO COMBO: DO COMBINATIONS OF ANTIPSYCHOTICS EVER MAKE ANY SENSE?
-
COMORBIDITY POLYPHARMACY: SIMULTANEOUS VS. SUCCESSIVE INTRODUCTION OF CO-PHARMACOTHERAPIES
-
SAFETY, TOLERABILITY, AND DRUG-DRUG INTERACTION CONCERNS IN POLYPHARMACOLOGY REGIMENS
-
WAKING UP TO EXCESSIVE DAYTIME SLEEPINESS IN PSYCHIATRY AND HOW TO MAKE WEARABLES WORK FOR MEASURING SLEEP AND ACTIVITY
-
SLEEP ASSESSMENTS AS PREDICTORS OF HEALTH RISK AND DEPRESSION
-
SMARTWATCH MEASUREMENTS AND CONTROLLED DEPRESSION: COMPARATIVE ANALYSES ON PHYSICAL ACTIVITY AND SLEEP
-
PMCID: PMC9008579. SLEEP AND ITS UTILITY FOR MENTAL HEALTH AND WELL-BEING RESEARCH: THE CASE FOR LONGITUDINAL MEASUREMENTS
-
DEPLOYING ARTIFICIAL INTELLIGENCE (AI) AND LARGE LANGUAGE MODELS (LLMS) IN PSYCHIATRY DRUG DEVELOPMENT
-
DESIGNING THE NEXT GENERATION OF STUDIES OF PSYCHEDELICS FOR DIFFICULT TO TREAT DEPRESSION
-
USING NEUROIMAGING TO ELUCIDATE PSYCHEDELIC MECHANISMS OF ACTION ON BRAIN CIRCUITS
-
LONG TERM OUTCOMES FROM PSILOCYBIN AND RESPONSE TO RE-DOSING FOR DIFFICULT TO TREAT DEPRESSION
-
CRITICAL METHODOLOGICAL DECISIONS IN PSYCHEDELIC DRUG TRIALS
-
REGULATORY PLENARY: AI-BASED TOOLS IN CNS DRUG DEVELOPMENT: A REGULATORY FRAMEWORK FOR CLINICAL TRIAL APPLICATIONS
-
ASCP LIFETIME AWARDEE TALK AND NASRALLAH AWARDEE
-
THE TYRANNY OF THE P-VALUE: EFFECT SIZE MATTERS
-
A SHORT JOURNEY THROUGH A 50 YEARS OF PROGRESS IN THE TREATMENT OF DEPRESSION
-
CLINICAL UPDATES ON NEUROTHERAPEUTICS: DISEASE STATE
-
SGAS VS MOOD STABILIZERS: THE PARADIGM SHIFT IN CORE TREATMENT FOR BIPOLAR DISORDER
-
AN UPDATE ON BIPOLAR DISORDER: EVIDENCE, CHALLENGES, AND SOLUTIONS
-
THE PHARMACOLOGIC TREATMENT OF SCHIZOPHRENIA: STATUS REPORT
-
EXCITING NEW FINDINGS FROM CLINICAL TRIALS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
-
SCHIZOPHRENIA POLYGENIC RISK IS NEGATIVELY ASSOCIATED WITH BODY MASS INDEX IN TWO POPULATION COHORTS
-
RETROSPECTIVE ANALYSIS OF REAL-WORLD TRANSITION STRATEGIES FOR XANOMELINE AND TROSPIUM CHLORIDE IN ADULT PATIENTS WITH SCHIZOPHRENIA
-
SLEEP ESTIMATION FROM LOW-FREQUENCY SMARTPHONE SENSORS VIA BAYESIAN HIDDEN MARKOV MODEL
-
NEURAL AND BEHAVIORAL EVIDENCE FROM REINFORCEMENT LEARNING CONVERGE IN SUPPORT OF RELAXED BELIEFS UNDER LSD
-
AUGMENTING DORSOLATERAL PREFRONTAL CORTEX-TARGETED TDCS WITH COGNITIVE REAPPRAISAL IN COCAINE USE DISORDER
-
MIXED AMPHETAMINE SALTS AND LISDEXAMFETAMINE AS ADJUNCTIVE TREATMENT FOR BIPOLAR DEPRESSION: POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS
-
BRAIN-TO-BRAIN MOVIE NEUROFEEDBACK REDUCES CRAVING IN OPIOID USE DISORDER
-
33959050; PMCID: PMC8093505.
-
EVALUATING HEPATIC EFFECTS OF SERIAL KETAMINE INFUSIONS FOR TREATMENT-RESISTANT BIPOLAR DEPRESSION
-
DRUG LIKING AND CRAVING OF INTRAVENOUS KETAMINE WHEN PRESCRIBED FOR THE TREATMENT OF MOOD DISORDERS IN A MONITORED SETTING: A DESCRIPTIVE ANALYSIS
-
COMBINED KETAMINE AND COGNITIVE BEHAVIORAL THERAPY: LEVERAGING METAPLASTICITY TO ENHANCE OUTCOMES
-
REPEATED KETAMINE INFUSIONS FOR TREATMENT-RESISTANT BIPOLAR DEPRESSION: A RANDOMIZED, MIDAZOLAM-CONTROLLED CLINICAL TRIAL
-
10.1177/20451253231202723. PMID: 37771417; PMCID: PMC10524067.
-
AMPA RECEPTOR BINDING POTENTIAL IS REDUCED IN THE ANTERIOR CINGULATE CORTEX OF FEMALE PATIENTS WITH PTSD
-
PMID: 31959988.
-
DURABILITY OF TMS TREATMENT FOR VETERANS WITH MDD EXAMINED VIA SIGNIFICANT PSYCHIATRIC EVENTS ASSOCIATED WITH RELAPSE (SPEAR): A PROPOSED NEW COMPOSITE OUTCOME MEASURE FOR HIGH SEVERITY/LOW FREQUENCY MENTAL HEALTH EVENTS
-
IS BRAIN INSULIN ACTION IMPLICATED IN THE BIOLOGY OF DEPRESSION? A PILOT NEUROIMAGING STUDY IN ADOLESCENTS
-
SEMAGLUTIDE IMPROVES HEALTH-RELATED QUALITY OF LIFE IN MAJOR DEPRESSIVE DISORDER INDEPENDENT OF MOOD CHANGE: EVIDENCE FOR METABOLIC AND MOTIVATIONAL PATHWAYS
-
MOVING BEYOND SLEEP: THE BROADER CONNECTION BETWEEN THE OREXIN SYSTEM AND PSYCHIATRIC DISORDERS
-
INCORPORATING NOVEL MUSCARINIC AGENTS FOR SCHIZOPHRENIA INTO CLINICAL PRACTICE: OVERCOMING CLINICAL INERTIA
-
6736(25)02365-7. PMID: 41763745
-
AI BEYOND EVIL ROBOTS: ENSURING TRANSFORMATIVE MEANS BETTER
-
UPDATE FROM FEDERAL AND OTHER FUNDING AGENCIES
-
NIAAA UPDATE: FOCUS ON THE MEDICATIONS DEVELOPMENT PROGRAM
-
PATIENT-CENTERED COMPARATIVE EFFECTIVENESS RESEARCH
-
ADVANCING THERAPEUTICS FOR SUBSTANCE USE DISORDERS THROUGH NIDA’S THERAPEUTICS DEVELOPMENT PROGRAM
-
PMID: 40395395; PMCID: PMC12089859. UPDATE FROM DEFENSE HEALTH AGENCY PSYCHOLOGICAL HEALTH RESEARCH PORTFOLIO
-
UPDATES FROM VETERAN HEALTH ADMINISTRATION (VA) RESEARCH INITIATIVES
-
NIMH UPDATE
-
DURABILITY OUTCOMES IN TREATMENT RESISTANT DEPRESSION
-
TRANSCRANIAL MAGNETIC STIMULATION: DURABILITY OF ANTI-DEPRESSANT RESPONSE
-
DURABILITY OF VAGUS NERVE STIMULATION TREATMENT-RESISTANT DEPRESSION: NEW, MORE COMPREHENSIVE FINDINGS FROM THE RECOVER TRIAL
-
BEYOND THE ACUTE COURSE: EXPLORING THE DURABILITY OF KETAMINE'S ANTIDEPRESSANT EFFECTS IN THE MAINTENANCE PHASE OF TREATMENT
-
15. PMID: 40834563.
-
40319349; PMCID: PMC12143125. HOW DURABLE ARE ACUTE EFFECTS OF PSILOCYBIN ON TREATMENT-RESISTANT DEPRESSION?
-
EVOLVING UNDERSTANDINGS OF PSYCHEDELICS IN CLINICAL RESEARCH
-
UNDERSTANDING PSILOCYBIN ADMINISTRATION: DOSE, PARTICIPANT CHARACTERISTICS, AND THERAPEUTIC CONTEXT
-
RECRUITING, RETAINING, AND TAILORING PSYCHEDELIC CLINICAL TRIALS FOR VULNERABLE POPULATIONS
-
EVALUATING THE CLINICAL UTILITY OF PSILOCYBIN THERAPY VERSUS OTHER PSYCHEDELIC DRUG INTERVENTIONS FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER
-
BUILDING COLLABORATIVE CAPACITY IN EARLY CAREER PSYCHOPHARMACOLOGY: STRATEGIES FOR EFFECTIVE PARTNERSHIPS ACROSS ACADEMIA, INDUSTRY, AND CLINICAL PRACTICE
-
THE EVOLVING NATURE OF ACADEMIC-INDUSTRY PARTNERSHIPS
-
PMCID: PMC11000613 TAKE-AWAYS FROM MY EXPERIENCE STARTING OUT IN CLINICAL PSYCHOPHARMACOLOGY RESEARCH
-
10.1056/NEJM1994052633021131530 – 1533 WHY DO WE NEED TEAM SCIENCE APPROACHES IN NEUROBIOLOGICAL AND CLINICAL STUDIES
-
39171416; PMCID: PMC11652247.
-
03008-5. PMID: 39054336; PMCID: PMC11272929. DEVELOPMENT OF ESKETAMINE. AN ACADEMIC -INDUSTRY DREAM COLLABORATION
-
ARE EARLY CAREER CLINICAL RESEARCHERS IN PSYCHIATRY AN ENDANGERED SPECIES?
-
THE YOUNG INVESTIGATOR AS A PLURIPOTENT STEM CELL: THE ROLE OF INDUSTRY-ACADEMIC PARTNERSHIPS IN A SUCCESSFUL CAREER
-
COMMUNICATION AND CONFLICT MANAGEMENT: PRACTICAL TOOLS FOR EFFECTIVE LEADERSHIP IN RESEARCH
-
ADVANCES IN DEPRESSION RESEARCH: A TRIBUTE TO NOLAN WILLIAMS
-
UNDERSTANDING AND HARNESSING THE OPIOID EFFECTS OF KETAMINE
-
NON-INVASIVE AMYGDALA NEUROMODULATION IN HUMANS WITH FOCUSED ULTRASOUND: NEUROBIOLOGICAL AND CLINICAL EFFECTS IN MOOD, ANXIETY, AND TRAUMA-RELATED DISORDERS
-
CLINICAL AND NEURAL OUTCOMES OF MAGNESIUM-IBOGAINE FOR TRAUMATIC BRAIN INJURY IN SPECIAL OPERATIONS FORCES VETERANS
-
PHOTOBIOMODULATION WITH NEAR INFRARED LIGHT: A NOVEL TREATMENT FOR PSYCHIATRIC DISORDERS
-
DOSE-DEPENDENT EFFECTS OF TRANSCRANIAL PHOTOBIOMODULATION ON BRAIN TEMPERATURE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A SPECTROSCOPY STUDY
-
6. PMID: 39370461. TRANSCRANIAL PHOTOBIOMODULATION FOR ALZHEIMER'S DISEASE
-
TRANSCRANIAL INFRARED LASER STIMULATION IMPROVES COGNITIVE PERFORMANCE AND INDUCES A BIPHASIC CEREBRAL PERFUSION RESPONSE IN REMITTED BIPOLAR DISORDER
-
UNCOVERING MECHANISMS OF PHOTOBIOMODULATION BEHIND CLINICAL CHANGES: EVIDENCE FROM NEUROIMAGING
-
LESSONS FROM TRANSFORMING THE PSYCHIATRIC HEALTHCARE SYSTEM: HOW TO IMPROVE OUTCOMES?
-
ALIGNMENT FOR PROGRESS: A MOVEMENT TO BRING CHANGE
-
ONE EXPERT BY EXPERIENCE JOURNEY
-
CHALLENGES OF BUILDING A LEARNING HEALTH SYSTEM FOR EARLY PSYCHOSIS CARE
-
TRANSFORMING THE HEALTHCARE SYSTEM WITH THE BIPOLAR ACTION NETWORK
-
DEVELOPING TREATMENTS FOR THE NON-MOTOR SYMPTOMS OF PARKINSON'S DISEASE
-
AB-300, A NOVEL 5-HT2A/2C AGONIST, REVERSES MOTIVATIONAL DEFICITS IN A TETRABENAZINE MODEL OF PARKINSON’S DISEASE APATHY
-
PSILOCYBIN THERAPY FOR DEPRESSION IN PARKINSON’S DISEASE
-
TARGETING SYNAPTIC LOSS IN PARKINSON’S DISEASE DEPRESSION WITH KETAMINE
-
ARTIFICIAL INTELLIGENCE: UNDERSTANDING THE PRESENT AND ANTICIPATING THE FUTURE
-
USING ARTIFICIAL INTELLIGENCE AND SOCIAL MEDIA DATA FOR POPULATION MENTAL HEALTH SURVEILLANCE
-
ASSESSING AI FOR CLINICAL CARE AND RESEARCH
-
BRIDGING AI INNOVATION AND CLINICAL TRIAL DATA IN PSYCHIATRY: MATHEMATICAL LIMITS AND CLINICAL CONSEQUENCES
-
WHAT TO KNOW ABOUT KETAMINE SAFETY: PATIENT MONITORING, NEUROTOXICITY, AND CONSIDERATIONS FOR SPECIAL PATIENT POPULATIONS
-
RACEMIC KETAMINE SIDE EFFECTS, ADVERSE REACTIONS, AND MONITORING
-
KETAMINE FOR DEPRESSION, BUT AT WHAT COST? EVIDENCE FOR NEUROTOXICITY FROM HUMAN AND ANIMAL STUDIES
-
USE OF KETAMINE FOR DEPRESSION IN SPECIAL POPULATIONS
-
THE DISCOVERY AND CLINICAL DEVELOPMENT OF (2R,6R)- HYDROXYNORKETAMINE FOR DEPRESSION AND PAIN
-
FROM KETAMINE METABOLITE TO CANDIDATE THERAPEUTIC: PRECLINICAL DISCOVERY OF (2R,6R)-HNK RELEVANCE TO DEPRESSION TREATMENT
-
PRECLINICAL DEVELOPMENT OF (2R,6R)-HYDROXYNORKETAMINE FOR HUMAN CLINICAL EVALUATION
-
CLINICAL DEVELOPMENT OF (2R,6R)-HYDROXYNORKETAMINE: ONGOING TRIALS IN TRD AND OCD AND PHASE 1 SAFETY, TOLERABILITY, AND PK/PD RESULTS IN HEALTHY VOLUNTEERS
-
EVALUATION OF THE (2R,6R)-HYDROXYNORKETAMINE AS A POTENTIAL CLINICAL USEFUL ANALGESIC AGENT: TRANSLATIONAL EXPERIENCE FROM PRECLINICAL TO HUMAN STUDY
-
NEW AND ANTICIPATED INTERVENTIONS FOR PERINATAL DEPRESSION
-
PATHOPHYSIOLOGICAL MECHANISMS OF PERINATAL DEPRESSION
-
EPIGENETIC BIOMARKERS IN POSTPARTUM DEPRESSION AND POSTPARTUM PSYCHOSIS
-
APPROVED AND POTENTIAL TREATMENTS FOR PPD
-
ADDICTION AND NEUROMODULATION IN PREGNANCY
-
THE FUTURE DSM: DESIGNING A SCIENTIFIC, INCLUSIVE, AND PRACTICAL DIAGNOSTIC MANUAL FOR MODERN PSYCHIATRY
-
THE FUTURE DSM: DESIGNING A SCIENTIFIC, INCLUSIVE, AND PRACTICAL DIAGNOSTIC MANUAL FOR MODERN PSYCHIATRY
-
STRUCTURE AND DIMENSIONS SUBCOMMITTEE
-
THE DSM SUBCOMMITTEE ON CANDIDATE BIOMARKERS AND BIOLOGICAL FACTORS
-
REGULATORY CHALLENGES: ASK THE EXPERTS
-
W1. THE PHASE 2/3 GAIN TRIAL OF THE FIRST-GENERATION P. GINGIVALIS GINGIPAIN INHIBITOR ATUZAGINSTAT IN MILD-TO-MODERATE PROBABLE ALZHEIMER’S DISEASE: NEW CEREBROSPINAL FLUID BIOMARKER DATA
-
W2. GALANTAMINE-MEMANTINE COMBINATION REGULATING THE KYNURENINE PATHWAY METABOLISM IN THE TREATMENT OF POST-STROKE DEPRESSION AND POST-STROKE COGNITIVE IMPAIRMENTS AND PREVENTION OF STROKE
-
W3. DYNAMIC CAUSAL MODELING OF TRIPLE-NETWORK CONNECTIVITY VARIES BY SUICIDE ATTEMPT HISTORY
-
W4. A REVIEW OF EVIDENCE AND AN ALGORITHM FOR USE OF PSYCHOPHARMACOLOGY IN THE TREATMENT OF TOBACCO USE DISORDER IN BEHAVIORAL HEALTH SETTINGS
-
W5. EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS IN SUBSTANCE USE DISORDERS WITH MEMANTINE, GALANTAMINE, N-ACETYLCYSTEINE, AND DOXAZOSIN/PRAZOSIN
-
W6. CHANGES IN SMOKING-RELATED OUTCOMES WITH TIRZEPATIDE IN INDIVIDUALS WITH METHAMPHETAMINE USE DISORDER WHO SMOKE
-
W7. CHANGES IN DEPRESSIVE SYMPTOMS WITH TIRZEPATIDE IN INDIVIDUALS WITH MODERATE-TO-SEVERE METHAMPHETAMINE USE DISORDER
-
W8. SAFETY AND TOLERABILITY OF 32-WEEK-LONG TREATMENT WITH TIRZEPATIDE IN INDIVIDUALS WITH MODERATE-TO-SEVERE METHAMPHETAMINE USE DISORDER
-
W9. FIRST DOSE TREATMENT EFFECTS WITH INJECTABLE WEEKLY AND MONTHLY BUPRENORPHINE (CAM2038) AND THE RELATIONSHIP BETWEEN BUPRENORPHINE PLASMA CONCENTRATIONS AND WITHDRAWAL SUPPRESSION IN PARTICIPANTS WITH OPIOID USE DISORDER
-
W10. A NEW DAWN FOR SOCIAL ANXIETY TREATMENT: CLINICAL ADVANCEMENT OF THE NOVEL V1AR ANTAGONIST, NTX-1472
-
W11. TREATMENT PATTERNS AMONG INCIDENT AND PERSISTENT PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD)
-
W12. THE IMPACT OF COMORBID PSYCHIATRIC DISORDERS ON MISCONDUCTS AMONG INCARCERATED INDIVIDUALS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A PRELIMINARY STUDY
-
W13. THE NEUROCHEMICAL AND ANXIOLYTIC-LIKE EFFECTS OF CENTANAFADINE IN PRECLINICAL ASSAYS IN THE RAT AND MOUSE
-
W14. GROWING TREND OF STIMULANT USE IN YOUNG PATIENTS MISDIAGNOSED WITH ADHD: A CASE-BASED SYSTEMATIC REVIEW
-
W15. EMOTIONAL DYSREGULATION SYMPTOM OUTCOMES IN ADULTS WITH ADHD TREATED WITH CENTANAFADINE: A POOLED POST HOC ANALYSIS OF TWO PHASE 3 TRIALS
-
W16. THE PERSISTENCE OF NEUROEPITHELIAL PROGENITORS IN NEOCORTICAL ORGANOIDS: IMPEDING ACCURATE MODELS FOR DRUG SCREENING IN NEURODEVELOPMENTAL DISORDERS
-
W17. LONG-TERM SAFETY AND TOLERABILITY OF CARIPRAZINE IN PEDIATRIC PATIENTS WITH AUTISM SPECTRUM DISORDER, BIPOLAR I DISORDER OR SCHIZOPHRENIA: FINAL RESULTS FROM AN OPEN-LABEL STUDY
-
W18. E2086, A SELECTIVE OREXIN RECEPTOR-2 AGONIST: STUDY FOR PROMOTING WAKEFULNESS IN PATIENTS WITH NARCOLEPSY TYPE 1
-
W19. THE COMPLEX MULTI-SYSTEM SYMPTOM INVENTORY (COMSS): A NEW INSTRUMENT TO ASSESS SYMPTOM FREQUENCY, IMPACT, AND POSTURAL DEPENDENCE ACROSS MULTIPLE CENTRAL AND PERIPHERAL AUTONOMIC SYMPTOM DOMAINS
-
W20. STATIC AND DYNAMIC DISRUPTIONS OF SALIENCE-NETWORK FLEXIBILITY IN VETERANS WITH COMORBID MILD TBI AND ALCOHOL USE DISORDER
-
W21. SUCCESSFUL EARLY TREATMENT OF ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS ASSOCIATED WITH SMALL CELL LUNG CANCER IN AN ELDERLY MALE PATIENT: A CASE REPORT
-
W22. GH001 EFFICACY IS INDEPENDENT OF PRIOR ANTIDEPRESSANT TREATMENT FAILURES IN TREATMENT-RESISTANT DEPRESSION: A POST HOC ANALYSIS OF A PHASE 2B RANDOMIZED CONTROLLED TRIAL
-
W23. EXAMINING THE IMPACT OF PATIENT-CENTERED APPROACHES ON THE ASSESSMENT AND MANAGEMENT OF COGNITIVE IMPAIRMENT IN MAJOR DEPRESSIVE DISORDER
-
W24. SELTOREXANT VERSUS QUETIAPINE EXTENDED RELEASE AS ADJUNCTIVE TREATMENT IN MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS: PHASE 3 TRIAL
-
W25. BENEFITS OF ADJUNCTIVE VAGUS NERVE STIMULATION IN DIFFICULT-TO-TREAT DEPRESSION: OUTCOMES OF A NATURALISTIC EUROPEAN COHORT (RESTORE-LIFE) COMPARED TO THE USA RECOVER RANDOMIZED CONTROLLED TRIAL
-
W26. POOLED INDIVIDUAL PATIENT DATA ANALYSIS OF THREE PHASE 2 TRIALS SUPPORTS VASOPRESSIN V1B RECEPTOR ANTAGONISM (BH-200 250 MG BID) AS AN ANTIDEPRESSANT MECHANISM FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
-
W27. GENETICALLY DEFINED SUBGROUP ANALYSIS REVEALS DIFFERENTIAL RESPONSE TO VASOPRESSIN V1B ANTAGONISM IN PATIENTS WITH MDD PRE-EXPOSED TO ANTIDEPRESSANT IN THE CURRENT EPISODE: POST-HOC ANALYSIS OF THE PHASE 2 OLIVE TRIAL
-
W28. CHARACTERISTICS OF DEPRESSION EPISODES TO INFORM REAL-WORLD HEALTH STATES FOR MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION
-
W29. LONGITUDINAL PROFILING OF TREATMENT TRAJECTORIES IN SSRI-ANCHORED MDD USING AGENTIC AI
-
W30. DIMENSIONS OF PSYCHEDELIC EXPERIENCE PREDICTING ANTIDEPRESSANT RESPONSE TO PSILOCYBIN ACROSS DIAGNOSES
-
W31. ANXIOUS DEPRESSION AS PREDICTOR OF CLINICAL OUTCOMES IN TREATMENT-RESISTANT DEPRESSION (ASCERTAIN-TRD)
-
W32. NEUROACTIVE STEROID CHANGES PRE-AND POST-KETAMINE DURING A DOUBLE-BLIND, CROSSOVER CLINICAL TRIAL: AN EXPLORATORY STUDY
-
W33. ASSOCIATION OF MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS WITH HEALTHCARE RESOURCE USE AND CARDIOVASCULAR AND METABOLIC CONDITIONS – ANALYSIS OF NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
-
W34. ESMETHADONE (REL-1017) IN PATIENTS WITH ANTIDEPRESSANT TACHYPHYLAXIS: A POST HOC EFFICACY ANALYSIS IN A PRE-RANDOMIZATION–DEFINED SUBGROUP
-
W35. PRECLINICAL BEHAVIORAL AND PHARMACOLOGICAL CHARACTERISTICS OF TN-001, A NOVEL, NON-HALLUCINOGENIC NEUROPLASTOGEN FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
-
W36. METABOLIC PROFILE OF ADJUNCTIVE LUMATEPERONE 42 MG IN MAJOR DEPRESSIVE DISORDER: A POOLED ANALYSIS OF 2 RANDOMIZED, PLACEBO-CONTROLLED TRIALS
-
W37. LUMATEPERONE 42 MG IN MAJOR DEPRESSIVE DISORDER: DEMOGRAPHIC AND CLINICAL SUBGROUPS EFFICACY ANALYSIS IN A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL
-
W38. EFFICACY OF LUMATEPERONE 42 MG FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: ANALYSIS OF DEMOGRAPHIC AND CLINICAL SUBGROUPS IN A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL
-
W39. PSYCHOPHARMACOLOGY OF ENX-104: A POTENT DOPAMINE (DA) D2/D3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH ANHEDONIA
-
W40. IMPACT OF GH001 ON DEPRESSIVE SYMPTOMS, ANXIETY, AND QUALITY OF LIFE IN TREATMENT-RESISTANT DEPRESSION: RESULTS FROM A PHASE 2B TRIAL
-
W41. RAPID AND SUSTAINED IMPROVEMENT IN ANHEDONIA FOLLOWING INHALED MEBUFOTENIN (GH001) TREATMENT IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
-
W42. EFFECTS OF DEXTROMETHORPHAN-BUPROPION (45MG/105MG) IN PARTICIPANTS WITH MAJOR DEPRESSIVE DISORDER AND ANXIOUS DISTRESS
-
W43. HJ-006: A NON-HALLUCINOGENIC SYNAPTOGENIC COMPOUND WITH RAPID AND SUSTAINED ANTIDEPRESSANT EFFICACY
-
W45. PSYCHOMOTOR DISTURBANCE AS A PREDICTOR OF TREATMENT RESPONSE IN MOOD DISORDERS: A SYSTEMATIC REVIEW
-
W46. THE MONOTHERAPY ANTIDEPRESSANT PIPELINE PROBLEM: ONLY 8 APPROVALS OUT OF 28 ATTEMPTS IN THE LAST 25 YEARS
-
W47. EARLY RESPONSE TO PSILOCYBIN IN ADULTS WITH TREATMENT-RESISTANT DEPRESSION AS A PREDICTOR FOR ANTIDEPRESSANT EFFICACY
-
W48. EARLY MOTIVATIONAL AND HEDONIC RESPONSES TO ANTIDEPRESSANTS IN MAJOR DEPRESSIVE DISORDER: A REAL-WORLD EVIDENCE STUDY
-
W49. REAL-WORLD EVIDENCE OF THE CLINICAL AND PREFERENCE IMPACT OF A PRESCRIPTION DIGITAL THERAPEUTIC FOR MAJOR DEPRESSIVE DISORDER: AN ONGOING PROSPECTIVE STUDY IN AN ACADEMIC HEALTH SYSTEM
-
W50. ANXIOLYTIC EFFECTS OF DEXTROMETHORPHAN-BUPROPION (45MG/105MG): POST HOC ANALYSES ACROSS TRIALS IN MAJOR DEPRESSIVE DISORDER
-
W51. MULTIMODAL IDENTIFICATION OF NEUROBIOLOGICAL SUBTYPES ASSOCIATED WITH KETAMINE RESPONSE IN TREATMENT-RESISTANT DEPRESSION USING NETRAAI
-
W52. OREXIN 2 RECEPTOR AGONISTS AS A POTENTIAL THERAPEUTIC APPROACH TO THE TREATMENT OF SLEEP-WAKE DISTURBANCE, FATIGUE, AND COGNITIVE DEFICIT IN NEUROPSYCHIATRIC DISEASE
-
W53. A NOVEL DISEASE-MODIFYING STRATEGY FOR NARCOLEPSY TYPE 1 – PRECLINICAL RATIONALE AND DEVELOPMENT ROADMAP FOR THE DOXA PLATFORM
-
W54. TARGETED ELIGIBILITY REVIEW CAN DECREASE THE NUMBER OF INAPPROPRIATE PARTICIPANTS ENROLLED IN CLINICAL TRIALS
-
W55. IMPACT-EXT: EVALUATING THE DURABILITY AND REDOSING OF TSND-201 (METHYLONE) FOR THE TREATMENT OF PTSD
-
W56. SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MSD-001 AFTER SINGLE DOSING IN HEALTHY ADULTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
-
W57. BLINDING INTEGRITY IN PSYCHEDELIC RANDOMIZED CONTROLLED TRIALS: A SYSTEMATIC REVIEW
-
W58. UNLOCKING MEDICINES FOR NEUROPSYCHIATRY BY ENHANCING ORAL ABSORPTION USING A LYMPHATIC-TARGETING PRODRUG TECHNOLOGY
-
W59. A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE FATTY ACID AMIDE HYDROLASE INHIBITOR PALMITOYLETHANOLAMIDE IN BIPOLAR DEPRESSION
-
W60. EFFICACY, SAFETY AND TOLERABILITY OF LYSERGIC ACID DIETHYLAMIDE FOR THE TREATMENT OF DEPRESSIVE SYMPTOMS: A META-ANALYSIS AND SYSTEMATIC REVIEW
-
(CRD420251063539).
-
W61. BEYOND MOOD: BROADER PSYCHOLOGICAL BENEFITS OF IV KETAMINE FOR MAJOR DEPRESSIVE DISORDER
-
W62. THE COMPLEX DIAGNOSTIC PROFILE OF PSYCHIATRIC OUTPATIENTS PRESENTING FOR THE TREATMENT OF BIPOLAR DEPRESSION
-
W63. SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS REDUCE SUICIDALITY, ALL-CAUSE MORTALITY, AND HOSPITALIZATION IN BIPOLAR DISORDER: A COHORT STUDY OF 1.23 MILLION ADULTS
-
W64. PRECLINICAL EFFICACY OF CONCOMITANT ADMINISTRATION OF NOVEL GSK3β INHIBITOR 4MT-A AND LITHIUM OROTATE
-
W65. THE NEUROBIOLOGICAL EFFECTS OF PSILOCYBIN IN TREATMENT RESISTANT BIPOLAR DEPRESSION: PROTOCOL AND INTERIM ANALYSIS OF CLINICAL OUTCOMES
-
W66. EFFECT OF CARIPRAZINE TREATMENT ON SLEEP AND MOOD SYMPTOMS IN PATIENTS WITH BIPOLAR I DEPRESSION AND BASELINE SLEEP DISTURBANCE: POST HOC ANALYSIS OF THREE RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIALS
-
W67. AN OPEN-LABEL, TWO-ARM STUDY OF KETAMINE’S EFFECTS ON FLUID COGNITION IN MOOD DISORDERS WITH AND WITHOUT PSYCHOSIS
-
W68. TIRZEPATIDE PRECIPITATING ACUTE LITHIUM TOXICITY IN STABLE BIPOLAR I DISORDER
-
W69. EFFECTS OF CARIPRAZINE ON SYMPTOMS OF ANXIETY: A POOLED POST HOC ANALYSIS OF DOUBLE-BLIND CLINICAL TRIALS IN PATIENTS WITH DEPRESSION
-
W70. REAL-WORLD IMPACT ON ANXIETY SYMPTOMS OF CARIPRAZINE AS ADJUNCTIVE TREATMENT IN MAJOR DEPRESSIVE DISORDER OR MONOTHERAPY IN BIPOLAR I DISORDER
-
W71. ANTIPSYCHOTIC SWITCHING AMONG PATIENTS WITH BIPOLAR I DEPRESSION AFTER INITIATING CARIPRAZINE VS LUMATEPERONE: A REAL-WORLD CLAIMS-BASED STUDY
-
W72. COMPARATIVE EFFICACY OF BUPROPION VS SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN ANTIDEPRESSANT-NAIVE, OBESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER
-
W73. EFFECT OF PSYCHEDELIC THERAPIES ON SLEEP IN PSYCHIATRIC DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
-
W74. IMPACT OF SELTOREXANT ON COGNITIVE PERFORMANCE OF ADULTS WITH MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS
-
W75. INTERMITTENT WHITE LIGHT AT 60 HZ AS A POTENTIAL NEUROSTIMULATION APPROACH FOR DEPRESSION: EFFECTS ON EEG ACTIVITY AND SAFETY IN HEALTHY HUMAN VOLUNTEERS
-
NCT07111390). W76. SAFETY AND EFFICACY OF FULL AND HALF-DOSE NEURONAVIGATED ACCELERATED THETA BURST TMS IN TREATMENT-NAïVE ADOLESCENT DEPRESSION
-
W77. REAL-WORLD EVIDENCE FROM LEGAL PSILOCYBIN-ASSISTED SERVICES IN OREGON: PSYCHEDELIC PREPAREDNESS AND EXPERIENTIAL PREDICTORS OF MENTAL HEALTH OUTCOMES
-
W78. PROTOCOL FOR REAL WORLD SAFETY AND EFFECTIVENESS STUDY OF PSILOCYBIN THERAPY
-
W79. REAL-WORLD EXPERIENCE AND IMPACT OF FATIGUE IN NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA FROM THE ASPIRE SURVEY STUDY
-
W80. ACTIVATION OF σ1R AND 5-HT2A PATHWAYS MODULATES NEUROINFLAMMATION, GLIAL REPAIR PROGRAMS, AND BBB RESPONSES IN DEMYELINATING CNS MODELS
-
W81. EXAMINING THE IMPACT OF TRAUMA ON KETAMINE'S EFFICACY IN BIPOLAR I/II DEPRESSION: A SECONDARY ANALYSIS FROM A RANDOMIZED, MIDAZOLAM-CONTROLLED TRIAL
-
W82. REAL-WORLD PERSISTENCE ON OLANZAPINE/SAMIDORPHAN VERSUS OTHER ORAL SECOND-GENERATION ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA
-
W83. USING ARTIFICIAL INTELLIGENCE/MACHINE LEARNING AND REAL-WORLD DATA TO IDENTIFY PATIENTS WITH SCHIZOPHRENIA FOR WHOM AN ARIPIPRAZOLE MONOHYDRATE LAI IS LIKELY TO BE A FAVORABLE TREATMENT OPTION
-
W84. ENDOCRINE BIOMARKERS OF SUICIDE RISK IN SCHIZOPHRENIA
-
W85. CLOZAPINE'S ANTAGONISM IS ROBUST AGAINST KNOWN DRD2 MUTATIONS
-
W86. IMPACT OF NEGATIVE SYMPTOMS ON HEALTHCARE RESOURCE UTILIZATION AND COSTS IN SCHIZOPHRENIA: A REAL-WORLD DATA ANALYSIS
-
95% CI: 0.99-1.39; P=0.06).
-
W87. ONSET, DURATION, AND INCIDENCE OF ADVERSE EVENTS BY DOSE AND TITRATION SCHEDULE OF XANOMELINE AND TROSPIUM CHLORIDE
-
W88. SUVN-L1101142, A MUSCARINIC M4 POSITIVE ALLOSTERIC MODULATOR (M4 PAM) FOR THE TREATMENT OF PSYCHOSIS-RELATED DISORDERS AND CONDITION
-
W89. OCCURRENCE OF URINARY RETENTION-RELATED ADVERSE EVENTS WITH XANOMELINE AND TROSPIUM CHLORIDE: RESULTS FROM THE 52-WEEK, OPEN-LABEL EMERGENT-5 TRIAL
-
W90. OLANZAPINE AND SAMIDORPHAN IN ADULTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER: UPDATED REVIEW OF CLINICAL DATA
-
W91. LONGITUDINAL TRENDS IN ANTIPSYCHOTIC POLYTHERAPY AND ASSOCIATED OUTCOMES IN SCHIZOPHRENIA
-
W92. EFFICACY AND SAFETY OF XANOMELINE AND TROSPIUM CHLORIDE FOR MANIA IN BIPOLAR DISORDER: DESIGN OF THE BALSAM-1 AND BALSAM-2 TRIALS
-
W93. REAL-WORLD IMPACT OF OLANZAPINE AND SAMIDORPHAN ON RATES OF RELAPSE AMONG YOUNG ADULTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER
-
W94. TRANSLATIONAL EVIDENCE FOR DOPAMINERGIC ALTERATION OF BASAL GANGLIA FUNCTIONAL CONNECTIVITY IN PERSONS WITH SCHIZOPHRENIA
-
W95. MEMANTINE FOR THE TREATMENT OF PRIMARY NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
-
W97. RISK OF SUICIDE ATTEMPT IN NEWLY DIAGNOSED ADHD WITH AND WITHOUT STIMULANT TREATMENT WITHIN THREE MONTHS OF DIAGNOSIS
-
W98. NOVEL ORAL RAPID-ACTING NEUROACTIVE STEROID FOR TREATMENT OF POSTPARTUM DEPRESSION: A PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL OF LPCN 1154A
-
W99. ACUTE TREATMENT OF POSTPARTUM PSYCHOSIS: AN UPDATE FROM THE MASSACHUSETTS GENERAL HOSPITAL POSTPARTUM PSYCHOSIS PROJECT
-
W100. RE104: A NOVEL SEROTONERGIC PSYCHEDELIC 4-OH-DIPT PRODRUG FOR THE TREATMENT OF POSTPARTUM DEPRESSION
-
W101. USE OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN FORENSIC PSYCHIATRY: A MULTI-SITE CANADIAN STUDY
-
W102. SUICIDE RISK OF THIRD-GENERATION ANTIPSYCHOTICS IN PERSONS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS
-
W103. ARIPIPRAZOLE ONCE-MONTHLY FOR PATIENTS LIVING WITH SCHIZOPHRENIA: NUMBER NEEDED TO TREAT, NUMBER NEEDED TO HARM, AND LIKELIHOOD TO BE HELPED OR HARMED
-
W105. MACHINE LEARNING DETECTION OF AROUSALS FROM AT-HOME SLEEP EEG DEVICE DEMONSTRATES COMPARABLE PERFORMANCE TO EXPERT RATERS IN SLEEP DISORDERS WITH AND WITHOUT ANTIDEPRESSANT USE
-
W106. HIGHER POLYGENIC RISK FOR MITOCHONDRIAL DYSFUNCTION IS ASSOCIATED WITH LOWER CEREBRAL BLOOD FLOW IN YOUTH WITH BIPOLAR DISORDER
-
W107. CHOROID PLEXUS VOLUME AS A BIOMARKER OF KETAMINE-RELATED IMPROVEMENT IN IRRITABILITY IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
-
W108. CHALLENGES AND STRATEGIES FOR TRAINING AND RETAINING THE NEXT GENERATION OF PHYSICIAN SCIENTISTS IN PSYCHIATRY DURING RESIDENCY AND FELLOWSHIP
-
W109. APPLYING SCIENTIFIC AND OPERATIONAL INSIGHTS FROM PRIOR CLINICAL TRIALS TO OPTIMIZE EFFICACY SIGNAL DETECTION IN A PROOF OF CONCEPT TRIAL WITH KYN-5356 IN COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA
-
W110. INITIAL PSYCHOMETRIC PROPERTIES OF THE ANHEDONIA INTERVIEW RATING SCALE CLINICIAN (AIRS) AND SELF-REPORT (AIRS-SR) AMONG POTENTIAL PSYCHIATRY STUDY PARTICIPANTS
-
W111. A FIRST-IN-HUMAN STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF KYN-5356, A FIRST-IN-CLASS INHIBITOR OF KYNURENINE AMINOTRANSFERASE II (KAT-II)
-
W112. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PARTICIPANTS RECEIVING COMP360 PSILOCYBIN TREATMENT FOR TREATMENT-RESISTANT DEPRESSION ACROSS TWO PIVOTAL PHASE 3 TRIALS
-
W113. CLOSING THE CARE GAP: EMBEDDING PTSD SCREENING IN PRIMARY CARE WORKFLOWS
-
W114. DURABILITY OF EFFICACY AND SAFETY OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION (TRD) ACROSS 26 WEEKS IN A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY
-
W115. ELUNETIROM, A FIRST-IN-CLASS, BRAIN-TARGETING, ANTIDEPRESSANT CANDIDATE IN PH2 DEVELOPMENT, TRIGGERS ROBUST BIOENERGETIC AND NEUROPLASTIC IMPROVEMENTS IN PRECLINICAL STUDIES
-
W116. LYSERGIDE TARTRATE (LSD; DT120) SAFETY PROFILE FROM PHASE 1 AND PHASE 2 CLINICAL STUDIES
-
W117. RATIONAL DEPRESCRIBING: ASCP EXPERT CONSENSUS FOR MOOD DISORDERS
-
W118. THE ASSOCIATION BETWEEN KETAMINE AND ESKETAMINE AND UROLOGICAL SYMPTOMS: REPORTS TO THE FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM (FAERS)
-
W119. EFFICACY AND SAFETY OF XANOMELINE/TROSPIUM CHLORIDE DURING TRANSITION FROM ATYPICAL ANTIPSYCHOTICS IN PARTICIPANTS WITH STABLE SCHIZOPHRENIA SYMPTOMS IN EMERGENT-5
-
W120. SILENCE IS GOLDEN: SPEECH PRODUCTION DURING PSILOCYBIN ADMINISTRATION SESSIONS FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
-
W121. A NOVEL INTERACTIVE DIGITAL LEARNING TOOL (DISCOVER TD®) FOR PSYCHIATRY RESIDENT TRAINING ON DIAGNOSIS AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS
-
W122. IMPACT OF A THREE-PART ONLINE EDUCATIONAL WEBINAR SERIES ON PSYCHIATRISTS’ KNOWLEDGE, COMPETENCE, AND CONFIDENCE IN DIAGNOSING AND MANAGING TARDIVE DYSKINESIA
-
W123. IDENTIFYING AND PREDICTING SYMPTOM TRAJECTORIES IN A BLENDED HYBRID DIGITAL MENTAL HEALTH CLINIC
-
W124. COGNITIVE IMPAIRMENT IN MAJOR DEPRESSIVE DISORDER: A PATIENT-PRIORITIZED TARGET FOR FUNCTIONAL RECOVERY
-
W125. EVALUATION OF VEDAI ACROSS CLINICAL PSYCHIATRY: A BLINDED PSYCHIATRIST-RATED STUDY
-
W126. PHARMACOLOGICAL VALIDATION OF NEUROKIT AS A PORTABLE, SENSITIVE AND REPRODUCIBLE TEST BATTERY IN EARLY CLINICAL CENTRAL NERVOUS SYSTEM (CNS) DRUG DEVELOPMENT
-
W127. MODELING CONTINUOUS-TIME NETWORK DYNAMICS OF PASSIVE SENSING AND ECOLOGICAL MOMENTARY ASSESSMENT DATA TO CHARACTERIZE TREATMENT RESPONSE IN DIGITAL MENTAL HEALTH CARE
-
T1. KETAMINE TREATMENT FOR NON-MOTOR SYMPTOMS OF PARKINSON'S DISEASE
-
T2. EFFECTS OF ITRACONAZOLE AND CARBAMAZEPINE ON THE PHARMACOKINETICS OF REMLIFANSERIN (ACP-204) IN HEALTHY ADULTS
-
T3. CORRELATION OF PLASMA P-TAU217 AND CSF P-TAU181 WITH CLINICAL DIAGNOSIS OF ALZHEIMER’S DISEASE: A CROSS-SECTIONAL STUDY OF 1,766 PARTICIPANTS IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE
-
T4. ASSESSING COMMUNITY PHARMACIST PREPAREDNESS TO IMPLEMENT METHADONE DISPENSING AND OBSERVATION
-
T5. UNDERSTANDING KRATOM’S EFFECTS AND ABUSE POTENTIAL: DESIGN OF THE FIRST FDA-FUNDED HUMAN STUDY
-
T6. MENSTRUAL PHASE-DRIVEN FRONTAL WHITE MATTER MICROSTRUCTURAL DYNAMICS TRACK PROGESTERONE AND CRAVING VARIABILITY IN WOMEN WITH SUBSTANCE USE DISORDERS
-
T7. SEMAGLUTIDE FOR THE TREATMENT OF OPIOID USE DISORDER: INTERIM ANALYSIS OF A PILOT RANDOMIZED CONTROLLED TRIAL
-
T8. OFFICE-BASED TREATMENT RETENTION AMONG PATIENTS WITH OPIOID USE DISORDER AND RECENT FENTANYL USE: EXTENDED-RELEASE INJECTABLE BUPRENORPHINE VS SUBLINGUAL BUPRENORPHINE
-
T9. REAL-WORLD UTILIZATION TRENDS OF WEEKLY AND MONTHLY INJECTABLE BUPRENORPHINE (CAM2038) IN THE UNITED STATES DURING THE ERA OF HIGH POTENCY SYNTHETIC OPIOIDS
-
T10. THE PHARMACOKINETIC PROPERTIES AND TARGET ENGAGEMENT EFFECTS OF THE NOVEL SEROTONIN TRANSPORTER MODULATOR, SNTX-2643, IN HEALTHY ADULTS
-
T11. EFFICACY AND SAFETY OF ULOTARONT IN ADULTS WITH GENERALIZED ANXIETY DISORDER: RESULTS FROM A PHASE 2/3 RANDOMIZED PLACEBO-CONTROLLED TRIAL
-
T12. MAZINDOL IR/SR: A 50-YEAR LEGACY REPOSITIONED AS A FIRST-IN-CLASS OREXIN–MONOAMINE MODULATOR FOR ADHD AND AROUSAL-RELATED DISORDERS
-
T13. COMPREHENSIVE MULTITARGET STRATEGY FOR TYPE 1 DIABETES AND ASSOCIATED NEUROLOGICAL/SLEEP DISORDERS (DANS): INTEGRATING STEM-CELL-DERIVED ISLET REPLACEMENT, IMMUNE MODULATION, AND NEURO-CIRCADIAN THERAPEUTICS
-
T14. INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF ADJUNCTIVE CARIPRAZINE TREATMENT TO PSYCHOSTIMULANTS IN ADULTS WITH ADHD: A PRELIMINARY STUDY
-
T15. ASRS OUTCOMES ACROSS CORE AND EXPANDED SYMPTOM DOMAINS AFTER 6 WEEKS OF CENTANAFADINE TREATMENT IN ADULTS WITH ADHD: A POOLED POST HOC ANALYSIS OF TWO PHASE 3 TRIALS
-
T16. EXECUTIVE FUNCTION SYMPTOM OUTCOMES IN ADULTS WITH ADHD TREATED WITH CENTANAFADINE: A POOLED POST HOC ANALYSIS OF TWO PHASE 3 TRIALS
-
T17. PATHOPHYSIOLOGICAL ANALYSIS OF AUTISM SPECTRUM DISORDER FOCUSING ON PERIPHERAL BLOOD MACROPHAGES
-
T18. PSYCHOTROPIC PRESCRIBING TRENDS WITHIN THE TEXAS JUVENILE JUSTICE DEPARTMENT FROM 2016 TO 2024
-
T19. SLEEP ARCHITECTURE IN PARTICIPANTS WITH INSOMNIA DISORDER CHARACTERIZED BY PHENOTYPE: OBJECTIVE SHORT SLEEP OR OBJECTIVE NORMAL SLEEP
-
T20. PSILOCYBIN-ASSISTED PSYCHOTHERAPY FOR CLUSTER B PERSONALITY DISORDERS AND COMORBID TREATMENT-RESISTANT DEPRESSION
-
T21. PHARMACOTHERAPIES FOR CO-OCCURRING STIMULANT USE DISORDER AND ADHD: A NETWORK META-ANALYSIS
-
T22. EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS (GLP-1RAS/GLP-1S) INTEGRATION IN PATIENTS UTILIZING ANTIPSYCHOTICS
-
T23. PREVALENCE OF PSYCHOTROPIC MEDICATION USE AMONG PATIENTS WITH CHRONIC AND IMMUNE-MEDIATED DISEASES: A REAL-WORLD ANALYSIS USING EPIC COSMOS
-
T24. PROSPECTIVE REPLICATION OF AN EEG BIOMARKER FOR PREDICTING CHANGES IN ATTENTION IN ALTO-203, AN H3 INVERSE AGONIST
-
T25. BH-200 (NELIVAPTAN), A VASOPRESSIN V1B RECEPTOR ANTAGONIST, IN GENETICALLY DEFINED SUBGROUPS OF MDD: PRECISION TARGETING OF HPA-AXIS DYSREGULATION IN THE OLIVE PHASE 2 PROGRAM
-
T26. A PHASE 2 CLINICAL TRIAL EXPLORING EFFICACY AND SAFETY OF THE VASOPRESSIN V1B ANTAGONIST BH-200, A TREATMENT FOR MDD, EVALUATING THE PERFORMANCE OF A GENETIC CLASSIFICATION TOOL TO IDENTIFY A SUBSET OF PATIENTS WITH LARGER IMPROVEMENT
-
T27. FORVISIRVAT (SP-624), A FIRST-IN-HUMAN SIRT6 ACTIVATOR WITH AN EPIGENETIC MECHANISM OF ACTION, CURRENTLY IN A PHASE 2B-3 STUDY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
-
T28. EFFECT OF KETAMINE ON INDIVIDUAL SYMPTOMS OF DEPRESSION IN A RANDOMIZED CONTROLLED TRIAL OF KETAMINE FOR TREATMENT-RESISTANT DEPRESSION
-
T29. EFFECTS OF SOLRIAMFETOL ON NEUROPSYCHOLOGICAL OUTCOMES IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA IN THE REAL-WORLD SURWEY STUDY
-
T30. METABOLIC PROFILES OF PARTICIPANTS WITH MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS IN A PHASE 3 TRIAL OF SELTOREXANT VERSUS QUETIAPINE EXTENDED RELEASE AS ADJUNCTIVE THERAPY
-
T31. DECREASE IN NEGATIVE MOOD AND INCREASE IN POSITIVE MOOD DURING 12 MONTHS OF VAGAL NERVE STIMULATION
-
T32. USE OF A PROSPECTIVE LEAD-IN STUDY TO ENHANCE ELIGIBILITY AND REDUCE SCREEN FAILURE IN MAJOR DEPRESSIVE DISORDER TRIALS
-
T33. METABOLIC BURDEN, INFLAMMATION, AND ESKETAMINE EFFICACY IN TREATMENT-RESISTANT MAJOR DEPRESSIVE EPISODES
-
T34. REAL-WORLD CLINICAL OUTCOMES OF PATIENTS SWITCHING TO TREATMENT WITH DEXTROMETHORPHAN-BUPROPION (45 MG/105 MG)
-
T35. EFFICACY AND SAFETY OF ESMETHADONE (REL-1017) IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND INADEQUATE RESPONSE TO STANDARD ANTIDEPRESSANTS: FINDINGS FROM TWO EARLY-TERMINATED PHASE 3 TRIALS
-
T36. LUMATEPERONE VERSUS OTHER ADJUNCTIVE ATYPICAL ANTIPSYCHOTICS FOR MAJOR DEPRESSIVE DISORDER: A NETWORK META-ANALYSIS OF COMPARATIVE EFFICACY AND SAFETY
-
T37. A PHASE IB STUDY EVALUATING SAFETY, PRELIMINARY EFFICACY, AND PUTATIVE BIOMARKERS OF NEUROPLASTICITY FOR THE NOVEL NEUROPLASTOGEN ZALSUPINDOLE (DLX-001) IN MAJOR DEPRESSIVE DISORDER
-
T38. REAL-WORLD EFFECTIVENESS OF INTRAVENOUS KETAMINE ON DEPRESSIVE SYMPTOMS, SUICIDAL IDEATION AND FUNCTIONAL IMPAIRMENT IN ADULTS WITH MOOD DISORDERS
-
T39. EVALUATING THE ASSOCIATION BETWEEN ANTIDEPRESSANT EFFICACY AND DISSOCIATION WITH KETAMINE IN TREATMENT-RESISTANT BIPOLAR DEPRESSION (TRBD)
-
T40. ADJUNCTIVE LUMATEPERONE 42 MG TREATMENT IN MAJOR DEPRESSIVE DISORDER: EFFICACY ACROSS PATIENT-REPORTED DEPRESSION SYMPTOMS
-
T41. FIRST ONSET AND DURATION OF TREATMENT-EMERGENT ADVERSE EVENTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH ADJUNCTIVE LUMATEPERONE 42 MG: A POOLED ANALYSIS OF 2 RANDOMIZED PLACEBO-CONTROLLED TRIALS
-
T42. REMISSION WITH LUMATEPERONE 42 MG ADJUNCTIVE TO ANTIDEPRESSANT THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: ANALYSIS OF SHORT-TERM AND LONG-TERM TRIALS
-
T43. PERIPHERAL BIOMARKER RELIABILITY IN MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS OF S100B
-
T44. EVALUATING THE ABUSE LIABILITY OF KETAMINE IN THE TREATMENT OF MOOD DISORDERS: A SYSTEMATIC REVIEW
-
T45. PATTERNS OF REAL-WORLD ANTIPSYCHOTIC SWITCHING AFTER INITIATING ADJUNCTIVE CARIPRAZINE OR LUMATEPERONE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
-
T46. COSTS ASSOCIATED WITH ADJUNCTIVE ATYPICAL ANTIPSYCHOTIC– RELATED WEIGHT GAIN AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER: AN ECONOMIC MODEL USING NUMBERS NEEDED TO HARM
-
T47. PRECLINICAL EVALUATION OF ROPANICANT, A NICOTINIC ACETYLCHOLINE α4β2 RECEPTOR ANTAGONIST IN ANIMAL MODELS OF DEPRESSION
-
T48. ROPANICANT (SUVN-911), AN α4β2 NACHR ANTAGONIST: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, EVALUATING THE EFFICACY AND SAFETY OF ROPANICANT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
-
T49. CONCURRENT ORAL ANTIDEPRESSANT USE AND CLINICAL OUTCOMES FROM INTRAVENOUS KETAMINE OR INTRANASAL ESKETAMINE IN A REAL-WORLD SAMPLE
-
T50. PSILOCYBIN TREATMENT FOR CHRONIC NEUROPATHIC PAIN AND DEPRESSION
-
T51. CONVERGENT VALIDITY AND TREATMENT RESPONSIVENESS OF THE PATIENT-RATED DEPRESSION CHECKLIST (PRDC)
-
T52. AN INVESTIGATION OF THE PUTATIVE ANTIDEPRESSANT MECHANISMS OF KETAMINE, REELIN, AND MU OPIOID RECEPTOR AGONISTS IN RATS AND IPSC-DERIVED CEREBRAL ORGANOIDS EXPOSED TO CHRONIC STRESS
-
T53. A LANGUAGE-DERIVED AFFECTIVE SENTIMENT DIMENSION OF KETAMINE RESPONSE IN DEPRESSION
-
T54. INTERPRETING PSYCHIATRIC DIGITAL PHENOTYPING DATA WITH LARGE LANGUAGE MODELS: A PRELIMINARY ANALYSIS
-
T55. A SIMULATION-BASED FRAMEWORK FOR CHARACTERIZING RISK IN CLINICALLY-DEPLOYED LARGE LANGUAGE MODELS
-
T56. AI-ENABLED PATIENT-DERIVED NEURONAL MODELS FOR MECHANISM-GUIDED ANTIDEPRESSANT SELECTION IN MAJOR DEPRESSIVE DISORDER
-
T57. SUSTAINED PHARMACODYNAMIC EFFECTS OF ESKETAMINE ON CORTICAL EXCITABILITY AND RESTING-STATE BRAIN ACTIVITY: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL
-
T58. ALTO-207, A FIXED-DOSE COMBINATION OF PRAMIPEXOLE AND ONDANSETRON, SUGGESTS EFFICACY IN TREATING MAJOR DEPRESSION: FINDINGS FROM A RANDOMIZED, DOUBLE-BLIND PHASE 2A TRIAL
-
T59. EFFECTS OF ALIXOREXTON ON PATIENT-REPORTED DISEASE SEVERITY, COGNITIVE FUNCTIONING, AND FATIGUE IN PATIENTS WITH NARCOLEPSY TYPE 1: RESULTS FROM THE PHASE 2 VIBRANCE-1 STUDY
-
T60. SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 VIBRANCE-1 STUDY OF THE OREXIN 2 RECEPTOR AGONIST ALIXOREXTON IN PATIENTS WITH NARCOLEPSY TYPE 1
-
T61. THE USE OF MAGNETOENCEPHALOGRAPHY (MEG) IN A FIRST-IN-HUMAN TRIAL TO DEMONSTRATE THE FUNCTIONAL CONSEQUENCES OF TARGET ENGAGEMENT BY DT-101, A NOVEL AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR
-
T62. CROSS TRIAL IDENTIFICATION OF A PREDICTIVE ENRICHMENT SUBGROUP FOR ESMETHADONE (REL 1017) IN MAJOR DEPRESSIVE DISORDER USING EXPLAINABLE MACHINE LEARNING
-
T63. PREDICTION OF HUMAN PHARMACOKINETIC PROFILES OF GLYPH PLATFORM PRODRUGS USING ANIMAL AND HUMAN DATA VIA A SEMI-MECHANISTIC PHARMACOKINETIC MODEL
-
T64. EVALUATING POTENTIAL ABUSE-RELATED ADVERSE EVENTS IN CLINICAL STUDIES OF PSYCHEDELICS AND NOVEL CENTRAL NERVOUS SYSTEM ACTIVE DRUGS TO INFORM LABELING AND SCHEDULING RECOMMENDATIONS: ISSUES, METHODS, AND RECOMMENDATIONS
-
T65. DT-101 – A NOVEL ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE RECEPTOR (AMPAR) POSITIVE ALLOSTERIC MODULATOR DEMONSTRATES FAVORABLE TOLERABILITY AND FUNCTIONAL BIOMARKERS IN PHASE 1 HEALTHY VOLUNTEER TRIAL
-
T66. USING ARTIFICIAL INTELLIGENCE/MACHINE LEARNING AND REAL-WORLD DATA TO IDENTIFY PATIENTS WITH EARLY STAGE BIPOLAR-I DISORDER FOR WHOM AN ARIPIPRAZOLE MONOHYDRATE LAI IS LIKELY TO BE A FAVORABLE TREATMENT OPTION
-
T67. DO NONDSM CRITERIA ENHANCE THE VALIDITY OF THE DSM-5 MIXED FEATURES SPECIFIER IN DEPRESSED PATIENTS?
-
T68. MULTIFOCAL NEGATIVE AFFECT: THE PREVALENCE AND CLINICAL PROFILE OF PSYCHIATRIC OUTPATIENTS WHO ARE DEPRESSED, ANXIOUS AND IRRITABLE
-
T69. THE MCINTYRE AND ROSENBLAT RAPID RESPONSE SCALE (MARRRS): A PSYCHOMETRIC EVALUATION OF PATIENTS WITH TREATMENT-RESISTANT BIPOLAR DEPRESSION
-
T70. CHANGES IN SLEEP PATTERNS WITH PSILOCYBIN-ASSISTED PSYCHOTHERAPY: AN EXPLORATORY ANALYSIS OF A RANDOMIZED CLINICAL TRIAL FOR TREATMENT-RESISTANT DEPRESSION
-
T71. PSILOCYBIN FOR ANHEDONIA: A SYSTEMATIC REVIEW OF CLINICAL AND PRECLINICAL EVIDENCE
-
T72. DON’T LET AI MAKE YOU MOODY: ASSESSING RACIAL BIAS IN LARGE LANGUAGE MODELS’ CLINICAL DECISION-MAKING IN MOOD DISORDERS
-
T73. EVALUATING THE POTENTIAL RISK OF KETAMINE-INDUCED HEPATOTOXICITY IN THE TREATMENT OF MOOD AND ANXIETY DISORDERS: A SYSTEMATIC REVIEW
-
T74. COGNITIVE OUTCOMES FOLLOWING SERIAL KETAMINE INFUSIONS IN TREATMENT-RESISTANT BIPOLAR I/II DEPRESSION: RESULTS FROM A RANDOMIZED, MIDAZOLAM-CONTROLLED TRIAL
-
T75. A PILOT STUDY OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR EMPAGLIFLOZIN IN MAJOR DEPRESSIVE DISORDER
-
T76. EFFICACY OF CARIPRAZINE FOR ANHEDONIA SYMPTOMS: A POOLED ANALYSIS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR I DEPRESSION
-
T77. DIFFERENTIAL EFFECTS OF TRANSCRANIAL PHOTOBIOMODULATION ON FUNCTIONAL NETWORK REORGANIZATION ACROSS CLINICAL POPULATIONS
-
T78. COMPARISON OF THE EFFICACY OF NEUROMODULATION THERAPIES IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
-
T79. HARMONIZING ADVERSE EVENT CRITERIA TO IMPROVE CNS-RELATED SAFETY AND ABUSE SIGNAL DETECTION IN CLINICAL TRIALS
-
T80. REAL-WORLD EXPERIENCE AND IMPACT OF COGNITIVE IMPAIRMENT IN NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA FROM THE ASPIRE SURVEY STUDY
-
T81. A HEAD-TO-HEAD ASSESSMENT OF VMAT2 TARGET OCCUPANCY OF ONCE-DAILY VALBENAZINE COMPARED TO DEUTETRABENAZINE EXTENDED RELEASE
-
T82. OPIOID USE IN PATIENTS WITH FIBROMYALGIA: A RETROSPECTIVE CLAIMS ANALYSIS
-
T83. COMPLICATIONS OF AN ABRUPT SWITCH FROM A FULL ANTAGONIST TO A PARTIAL D2 AGONIST
-
T84. IMPACT-2: A PHASE 2 RANDOMIZED, DOSE-RESPONSE TRIAL OF TSND-201 (METHYLONE) FOR THE TREATMENT OF PTSD
-
T85. SYMPTOMS OF POST-TRAUMATIC STRESS DISORDER IN INDIVIDUALS WITH MODERATE-TO-SEVERE METHAMPHETAMINE USE DISORDER AND CHANGES WITH TIRZEPATIDE TREATMENT
-
T86. A SYSTEMATIC LITERATURE REVIEW ON ANTI-PSYCHOTIC UTILIZATION IN MINORITY POPULATIONS AND KEY CLINICAL CONSIDERATIONS
-
T87. DT120 (LYSERGIDE, LSD): ASSESSING THE POTENTIAL RISK OF CARDIAC VALVULOPATHY AFTER CHRONIC DOSING IN RATS
-
T88. REAL-WORLD TREATMENT PATTERNS IN MANIC/MIXED BIPOLAR I DISORDER: A US RETROSPECTIVE COHORT STUDY
-
T89. ML-007C-MA, A NOVEL INVESTIGATIONAL M1/M4 MUSCARINIC AGONIST IN PHASE 2 DEVELOPMENT FOR THE TREATMENT OF SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS
-
T90. EFFICACY OF XANOMELINE AND TROSPIUM CHLORIDE ACROSS SYMPTOM DOMAINS IN ADULTS WITH SCHIZOPHRENIA: RESULTS FROM THE 52-WEEK, OPEN-LABEL EMERGENT-5 CLINICAL TRIAL
-
T91. THE METABOLIC-COGNITIVE PATHWAY IN SCHIZOPHRENIA: EXAMINING FASTING GLUCOSE, LIPIDS, AND BLOOD PRESSURE AS PREDICTORS OF COGNITIVE IMPAIRMENT AND DEMENTIA RISK
-
T92. INPATIENT INITIATION OF THE LONG-ACTING INJECTABLE ANTIPSYCHOTIC ARIPIPRAZOLE LAUROXIL FOR THE TREATMENT OF ACUTE EXACERBATIONS OF SCHIZOPHRENIA
-
T93. SAFETY AND EFFICACY OF ARIPIPRAZOLE LAUROXIL IN AN OUTPATIENT SETTING AFTER INITIATION DURING HOSPITALIZATION FOR AN ACUTE EXACERBATION OF SCHIZOPHRENIA
-
T94. LB-102 FOR ACUTE SCHIZOPHRENIA IN ADULTS: RESULTS FROM THE PHASE 2 NOVA1 CLINICAL TRIAL, FOCUSED ON PANSS TOTAL SCORE RESPONDER AND CGI-S REMITTER RATES
-
T95. ROLE OF GLP-1 RECEPTOR AGONISTS IN MANAGING ANTIPSYCHOTIC-RELATED METABOLIC DYSFUNCTION AND WEIGHT GAIN
-
T96. REAL-WORLD USE OF XANOMELINE AND TROSPIUM CHLORIDE IN SCHIZOPHRENIA: PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES
-
T97. REAL-WORLD COMPARISON OF OLANZAPINE/SAMIDORPHAN VS OLANZAPINE: AN ASSESSMENT OF TREATMENT PATTERNS AND ACUTE CARE EVENTS AMONG PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER
-
T98. REAL-WORLD OUTCOMES AND PSYCHOLOGICAL PREDICTORS IN AN 8-WEEK HYBRID DIGITAL CLINIC FOR DEPRESSION AND ANXIETY
-
T99. RESTING-STATE EEG SIGNATURES OF SUICIDAL IDEATION SEVERITY AND INTENSITY IN TREATMENT-RESISTANT DEPRESSION: PRELIMINARY BASELINE DATA FROM TWO ONGOING CLINICAL TRIALS
-
T100. ATTITUDES TOWARD ARTIFICIAL INTELLIGENCE CLINICAL DECISION SUPPORT IN PSYCHIATRY TRAINING: CURRENT EVIDENCE AND FUTURE DIRECTIONS
-
T101. THE NATIONAL PREGNANCY REGISTRY FOR PSYCHIATRIC MEDICATIONS: RISK OF MAJOR MALFORMATIONS FOLLOWING FETAL EXPOSURE TO SECOND GENERATION ANTIPSYCHOTICS
-
T102. PREGNANCY OUTCOMES AFTER FIRST-TRIMESTER EXPOSURE TO VORTIOXETINE: PROSPECTIVE OUTCOMES FROM THE MGH NATIONAL PREGNANCY REGISTRY FOR PSYCHIATRIC MEDICATIONS
-
T103. RISK OF MAJOR MALFORMATIONS FOLLOWING FIRST TRIMESTER EXPOSURE TO CARIPRAZINE: PRELIMINARY DATA FROM THE MGH NATIONAL PREGNANCY REGISTRY FOR PSYCHIATRIC MEDICATIONS
-
T104. ARTIFICIAL INTELLIGENCE–ASSISTED PARTICIPANT RECRUITMENT FOR PSYCHIATRIC CLINICAL TRIALS: A COMPARATIVE EVALUATION OF LEAD QUALITY AND ENGAGEMENT
-
T105. ACTIVE AND PASSIVE DIGITAL PHENOTYPING TO MEASURE OUTCOMES IN A 12-MONTH STUDY OF XANOMELINE/ TROSPIUM CHLORIDE IN SCHIZOPHRENIA: LONGITUDINAL PREDICTION OF TOTAL CHANGES WITH EARLY LEVELS OF PHYSICAL ACTIVITY
-
T106. EXOSOMES AND A NOVEL MITOCHONDRIAL MECHANISM OF EPIGENETIC REGULATION OF BRAIN PLASTICITY IN TREATMENT RESISTANT DEPRESSION
-
T107. PERSPECTIVES OF NURSE PRACTITIONERS AND PHYSICIAN ASSOCIATES ON PRESENTING LONG-ACTING INJECTABLES TO ADULTS WITH SCHIZOPHRENIA: A DELPHI PANEL STUDY
-
T108. A NOVEL, BRAIN PENETRANT KAT-II INHIBITOR, KYN-5356, REDUCES BRAIN KYNURENIC ACID LEVELS AND ENHANCES GLUTAMATERGIC AND CHOLINERGIC TRANSMISSION
-
T109. RACIAL DIFFERENCES IN ANTIDEPRESSANT INITIATION AND OUTCOMES AFTER A ONE-TIME PSYCHIATRIC CONSULTATION: A MIXED-METHODS STUDY
-
T110. EFFICACY AND SAFETY OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION (TRD) IN TWO PHASE 3 DOUBLE-BLIND RANDOMIZED CONTROLLED STUDIES
-
T111. ESKETAMINE NASAL SPRAY FOR RELAPSE PREVENTION IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION: A POST HOC ANALYSIS OF PREDICTORS OF RELAPSE IN PLACEBO-TREATED PATIENTS IN SUSTAIN-1
-
T112. VALIDATION OF THE NEUROKIT PLATFORM FOR CENTRAL NERVOUS SYSTEM PHARMACODYNAMIC ASSESSMENT IN HEALTHY VOLUNTEERS
-
T113. CONNECTEDNESS AS A MECHANISM OF CHANGE IN PSILOCYBIN-ASSISTED COGNITIVE BEHAVIORAL THERAPY
-
T114. NEXT-GENERATION PHARMACOTHERAPIES FOR MOOD AND ANXIETY DISORDERS: A COMPREHENSIVE REVIEW OF PHASE II/III DRUG DEVELOPMENT ACROSS DIVERSE MECHANISMS
-
T115. OPEN-LABEL, RANDOMIZED STUDY TO ASSESS SAFETY AND EFFICACY OF SLOW AND ACCELERATED SWITCHING TO XANOMELINE/TROSPIUM FROM STANDARD OF CARE ATYPICAL ANTIPSYCHOTICS IN PARTICIPANTS WITH SCHIZOPHRENIA
-
T116. FROM NIGHTMARES TO DEPRESSION: AGE-STRATIFIED NEUROPSYCHIATRIC EFFECTS OF MONTELUKAST
-
T117. IMPROVEMENT OF PREDOMINANT NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA ON PALIPERIDONE PALMITATE 6-MONTH LONG-ACTING INJECTABLE: POST-HOC ANALYSIS OVER 3 YEARS
-
T118. EFFICACY OF SUBLINGUAL DEXMEDETOMIDINE IN THE HOME SETTING FOR REDUCTION IN AGITATION ACROSS BASELINE SEVERITY OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
-
T119. LONG-TERM METABOLIC AND CARDIOVASCULAR SAFETY AND TOLERABILITY WITH XANOMELINE AND TROSPIUM CHLORIDE: POOLED RESULTS FROM EMERGENT-4 AND EMERGENT-5
-
T120. SCHIZOPHRENIA-RELATED HOSPITALIZATION HISTORY BEFORE LONG-ACTING INJECTABLE ANTIPSYCHOTIC INITIATION AND ITS ASSOCIATION WITH SUBSEQUENT ADHERENCE AND HOSPITALIZATIONS AMONG DUAL-ELIGIBLES: THE CRITICAL PERIOD STUDY
-
T121. OUTCOMES IN DEPRESSION SYMPTOMATOLOGY WITH HIGH AND LOW LEVELS OF SUICIDAL IDEATION
-
T122. REAL-WORLD SAFETY AND EFFECTIVENESS OF LURASIDONE IN CHINESE CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A POST-HOC ANALYSIS OF A POST-MARKETING SURVEILLANCE STUDY
-
T123. REAL-WORLD EVIDENCE OF CLINICAL TREATMENT RESPONSE FOLLOWING INTRAVENOUS RACEMIC KETAMINE VERSUS INTRANASAL ESKETAMINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
-
T124. MULTICLASS ENVIRONMENTAL TOXICANTS FOUND IN CEREBROSPINAL FLUID (CSF) AND PLASMA SAMPLES FROM PREGNANT WOMEN: POTENTIAL ASSOCIATIONS WITH POSTPARTUM DEPRESSIVE SYMPTOMS
-
T125. CONTINUOUS MULTIMODAL PASSIVE MONITORING OF DEPRESSIVE SYMPTOMS VIA SMARTPHONE: CLINICAL VALIDATION OF A NOVEL DIGITAL HEALTH TECHNOLOGY
-
T126. COMPARABLE SYMPTOM IMPROVEMENT WITH ELECTROCONVULSIVE THERAPY AND ESKETAMINE IN TRANSGENDER AND GENDER NON-CONFORMING ADULTS WITH TREATMENT-RESISTANT DEPRESSION
-
ASCP Annual Meeting 2026 — Abstracts